Diego A. Díaz-García, Medical Oncologist /CEO/Founder at CánCare – High Specialty in Oncology and Medical Oncologist at Angeles del Carmen Hospital, shared a post on X:
“CRISPR 2.0–engineered T cell therapies
Base and prime editing enable precise, programmable genome modification in T cells, reducing unwanted edits seen with CRISPR Cas9.
These platforms aim to enhance T cell fitness, expand targetable antigens, and simplify manufacturing, with multiple trials now underway in haematological and solid tumours.”
Title: Next-generation T cell immunotherapies engineered with CRISPR base and prime editing: challenges and opportunities
Authors: Karl Petri, E. D’Ippolito, A. Künkele, Ulrike Köhl, Dirk H. Busch, H. Einsele, M. Hudecek
Read the Full Article.
More posts featuring Diego A. Díaz-García.
